Clinical Trial Search

Primary: Overall Survival (OS) — 14.1; 9.9 Months

Primary: Overall Survival (OS) — 10.78; 7.46 months — p=< 0.001

Primary: Overall Survival (OS) — 12.7; 10.9 Months — p=0.0034

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 91.7; 58.3; 75.0; 58.3 percentage of participants

Primary: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16 — 16.7; 40.3 Percentage of participants — p==0.0030

Primary: Proportion of Participants Cured Based on a Collarette Score at Day 43. — 0.439; 0.072 Proportion cured

Primary: Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior…

Primary: The Proportion of Participants Cured Based on Their Collarette Score of 0 for the Upper Eyelid. — 0.547; 0.122 Proportion cured

Primary: Anti-glycoprotein E (Anti-gE) Antibody Concentrations, as Assessed in the Long Term Follow-up (LTFU) Phase of the Current ZOSTER-073 Study — 3729.8; 3440.2; 3075.8 mIU/mL

Primary: Overall Survival (OS) — 10.5; 10.7 months — p=0.3668

Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score — -22.75; -23.95; -17.42 score on a scale — p=0.0136

Primary: Number of Participants With Favorable Outcome on the Simplified Modified Rankin Scale (sMRSq) — 5; 7; 1; 1 participants

Primary: Number of Participants With Treatment Emergent Adverse Event (AE) and Treatment Related AE — 7; 4; 5; 4 Participants

Primary: Induction Study: Percentage of Participants Who Achieved Clinical Remission by Crohn's Disease Activity Index (CDAI) at Week 10 — 32.9; 25.7; 19.8; 26.7 percentage of…

Primary: Satisfaction With Pain Relief — 8.70; 8.85 score on a scale — p=0.70